Abstract
Systemic light chain amyloidosis (AL) is a kind of plasma disease which leads to tissue and organ dysfunction caused by the deposit of monoclonal immunoglobulin light chain. Autologous peripheral blood stem cell transplantation (APBSCT) is the first-line treatment for patients with confirmed AL. For the ones unengaging the transplantation, chemotherapy can improve the response rate and prolong the survival. Current ways of chemotherapy include proteasome inhibitors, immunomodulatory agents and alkylating agents. In recent years, immunotherapy represented by NEOD001 and antibodies to serum amyloid P component (SAP) has showed to be significantly effective. The clinical response of clarithromycin, doxycycline and epigallocatechin gallate (EGCG) is still under exploration. The article reviews the advance in treatment of AL. Key words: Amyloidosis; Peripheral blood stem cell transplantation; Immunotherapy; Chemotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
